Evidence map›Paper›PMID 34678947›Full record

ArticleToxics2021

Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine).

Pascal Kintz, Laurie Gheddar, Camille Paradis, Mickael Chinellato, Alice Ameline, Jean-Sébastien Raul, Magali Oliva-Labadie

Open access · goldAbstract read
In one paragraph

Article in Toxics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pascal KintzInstitut de Médecine Légale, 11 rue Humann, 67000 Strasbourg, France.ORCID 0000-0002-4174-5362
Laurie GheddarInstitut de Médecine Légale, 11 rue Humann, 67000 Strasbourg, France.
Camille ParadisCentre Antipoison et de Toxicovigilance, Groupe Hospitalier Pellerin, Place Amélie Raba Léon, CEDEX, 33076 Bordeaux, France.ORCID 0000-0002-4892-1496
Mickael ChinellatoService des Urgences, Centre Hospitalier de Marmande, 76 rue du Dr Courret, 47200 Marmande, France.
Alice AmelineInstitut de Médecine Légale, 11 rue Humann, 67000 Strasbourg, France.
Jean-Sébastien RaulInstitut de Médecine Légale, 11 rue Humann, 67000 Strasbourg, France.
Magali Oliva-LabadieCentre Antipoison et de Toxicovigilance, Groupe Hospitalier Pellerin, Place Amélie Raba Léon, CEDEX, 33076 Bordeaux, France.
Institut de Médecine et d'Epidémiologie Africaines · FRCentre Hospitalier d'Albi · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 43-year-old male, sport coach, presented him-self at the Emergency unit of a local hospital for epigastric pain, myalgia pain and severe headache. He claimed having used for some days a combination of GW1516 (cardarine), a peroxisome proliferator-activated receptor delta agonist (PPAR- δ) and MK2866 (ostarine), a selective androgen receptor modulator (SARM) to gain skeletal muscles. Cytolysis with marked increase of alanine aminotransferase or ALT (up to 922 UI/L) and aspartate aminotransferase or AST (up to 2558 UI/L) and massive rhabdomyolysis with elevated creatine phosphokinase or CPK (up to 86435 UI/L) were the main unusual biochemistry parameters. Using a specific liquid chromatography coupled to tandem mass spectrometry method, cardarine and ostarine tested positive in blood at 403 and 1 ng/mL, respectively. In urine, due to extensive metabolism, the parent GW1516 was not identified, while ostarine was at 88 ng/mL. Finally, both drugs were identified in hair (2 cm in length, brown in colour), at 146 and 1105 pg/mg for cardarine and ostarine, respectively. This clearly demonstrates repetitive abuse over the last 2 months. Asthenia was persistent for 2 weeks and 6 weeks after the admission, the subject fully recovered.

Indexed as

bloodcardarineclinicaldopingGW1516hairMK2866ostarinePPAR- δSARM

Identifiers

PMID34678947
PMCPMC8538264
OpenAlexW3203853832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.